Eisai to Present the Latest Data on Long-Term, Real-World Treatment with Lecanemab at the AD/PD(TM) 2026 Annual Meeting TOKYO, Mar 11, 2026 – (JCN Newswire) […]
Tag: Eisai
Eisai: Update on the Co-Promotion of the Oral Antifungal Agent Nailin Capsules 100mg in Japan
Eisai: Update on the Co-Promotion of the Oral Antifungal Agent Nailin Capsules 100mg in Japan TOKYO, Mar 5, 2025 – (JCN Newswire) – Sato Pharmaceutical […]
Eisai Receives Regulatory Review Outcome for Lecanemab as a Treatment for Early Alzheimer’s Disease in Australia
Eisai Receives Regulatory Review Outcome for Lecanemab as a Treatment for Early Alzheimer’s Disease in Australia TOKYO and CAMBRIDGE, Mass., Mar 4, 2025 – (JCN […]
Eisai Named to List of The Time 100 Most Influential Companies
TOKYO, June 3, 2024 – (JCN Newswire) – TIME reveals the TIME100 Most Influential Companies list, highlighting companies making an extraordinary impact around the world. […]
Eisai Strengthens Venture Investment Business Aimed at Accelerating Drug Discovery Innovation and Establishment of Ecosystem Platform
Eisai Strengthens Venture Investment Business Aimed at Accelerating Drug Discovery Innovation and Establishment of Ecosystem Platform TOKYO, June 3, 2024 – (JCN Newswire) – Eisai […]